Home › Steatotic Liver Disease › North Carolina
Steatotic Liver Disease clinical trials in North Carolina
13 studies for Steatotic Liver Disease are looking for participants at sites in North Carolina.
Cities in North Carolina
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- and 2 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 5, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- and 3 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 5, 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- and 5 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
RecruitingObservational study
Ages 18 to 42 · Women · Updated Apr 13, 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
Recruiting
Ages 18 and older · All sexes · Updated Apr 3, 2026 · NCT07495332From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.